Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis

European Journal of Neurology

Volumn 23, Issue 1, 2016, Pages 62-67

  Behrens, Janina R ^a   Rasche, Ludwig ^a   Gieß, Rene M ^a   Pfuhl, Catherina ^a   Wakonig, Katharina ^a   Freitag, Erik ^a   Deuschle, Katrin ^a   Bellmann Strobl, Judith ^a   Paul, Friedemann ^a   Ruprecht, Klemens ^a   Dörr, Jan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

25 hydroxyvitamin D; Bioavailable vitamin D; Clinically isolated syndrome; Multiple sclerosis; Risk factor; Vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; GLATIRAMER; VITAMIN D BINDING PROTEIN; 25-HYDROXYVITAMIN D; CALCIFEDIOL; ERGOCALCIFEROL; VITAMIN D;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; BLOOD; MIDDLE AGED; YOUNG ADULT;

ADULT; BIOLOGICAL AVAILABILITY; CALCIFEDIOL; ERGOCALCIFEROLS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RISK FACTORS; VITAMIN D; YOUNG ADULT;

EID: 84954510580     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12788     Document Type: Article

References (35)

1. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Am Med Assoc 2006; 296: 2832-2838.
2. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-65.
3. Salzer J, Hallmans G, Nyström M, et al. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012; 79: 2140-2145.
4. Martinelli V, Dalla Costa G, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2014; 20: 147-155.
5. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193-203.
6. Runia TF, Hop WCJ, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012; 79: 261-266.
7. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012; 72: 234-240.
8. Bikle DD, Gee E, Halloran B, et al. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986; 63: 954-959.
9. Powe CE, Evans MK, Wenger J, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991-2000.
10. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
11. Van der Mei IAF, Ponsonby A-L, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007; 254: 581-590.
12. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373-378.
13. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005; 10: 94-111.
14. Kramer J, Diehl A, Lehnert H. Epidemiological study on the dimension of vitamin D deficiency in North Germany. Dtsch Med Wochenschr (1946) 2014; 139: 470-475.
15. Reusch J, Ackermann H, Badenhoop K. Cyclic changes of vitamin D and PTH are primarily regulated by solar radiation: 5-year analysis of a German (50 degrees N) population. Horm Metab Res 2009; 41: 402-407.
16. Klenk J, Rapp K, Denkinger MD, et al. Seasonality of vitamin D status in older people in Southern Germany: implications for assessment. Age Ageing 2013; 42: 404-408.
17. Ringe JD, Kipshoven C. Vitamin D-insufficiency: an estimate of the situation in Germany. Dermatoendocrinol 2012; 4: 72-80.
18. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
19. Chun RF. New perspectives on the vitamin D binding protein. Cell Biochem Funct 2012; 30: 445-456.
20. Bouillon R, Van Assche FA, Van Baelen H, Heyns W, De Moor P. Influence of the vitamin D-binding protein on the serum concentration of 1, 25-dihydroxyvitamin D3. Significance of the free 1, 25-dihydroxyvitamin D3 concentration. J Clin Invest 1981; 67: 589-596.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983; 33: 1444-1452.
22. Bhan I, Powe CE, Berg AH, et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 2012; 82: 84-89.
23. Ashraf AP, Alvarez JA, Dudenbostel T, et al. Associations between vascular health indices and serum total, free and bioavailable 25-hydroxyvitamin D in adolescents. PLoS One 2014; 9: e114689.
24. Ying H-Q, Sun H-L, He B-S, et al. Circulating vitamin D binding protein, total, free and bioavailable 25-hydroxyvitamin D and risk of colorectal cancer. Sci Rep 2015; 5: 7956.
25. Chun RF, Peercy BE, Orwoll ES, et al. Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol 2014; 144: 132-137.
26. Niino M, Sato S, Fukazawa T, et al. Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. J Neuroimmunol 2015; 279: 40-45.
27. Rinaldi AO, Sanseverino I, Purificato C, et al. Increased circulating levels of vitamin D binding protein in MS patients. Toxins 2015; 7: 129-137.
28. Smolders J, Peelen E, Thewissen M, et al. Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis. Mult Scler 2014; 20: 433-437.
29. Taes YEC, Goemaere S, Huang G, et al. Vitamin D binding protein, bone status and body composition in community-dwelling elderly men. Bone 2006; 38: 701-707.
30. Wang Y, Wang Y-J, Zhan J-K, et al. Vitamin D binding protein affects the correlation of 25(OH)D and frailty in the older men. Int J Endocrinol 2014; 2014: 543783.
31. Pekkinen M, Saarnio E, Viljakainen HT, et al. Vitamin D binding protein genotype is associated with serum 25-hydroxyvitamin D and PTH concentrations, as well as bone health in children and adolescents in Finland. PLoS One 2014; 9: e87292.
32. Steckley JL, Dyment DA, Sadovnick AD, et al. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 2000; 54: 729-732.
33. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
34. Becklund BR, Severson KS, Vang SV, DeLuca HF. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci USA 2010; 107: 6418-6423.
35. Lucas RM, Ponsonby A-L, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011; 76: 540-548.